SRP® Technology Intellectual Property
Epitopix has a family of patents protecting SRP® Technology and other Epitopix discoveries. This patent portfolio consists of more than 70 granted patents in the U.S., Europe and other countries, a score of pending patent applications and numerous patent drafts. Most major geographic markets of significance to animal health have been protected. We expect this proprietary base to grow and strengthen the technology thus lengthening the exclusivity period of product protection.
The key patented technology for Epitopix SRP® vaccine products is based on inducing host immunity against certain cell wall components of common Gram (-) and Gram (+) bacteria. These cell wall antigens are called Siderophore Receptor and Porin proteins, collectively referred to as SRP®, and our patented immunization and manufacturing methods as SRP® Technology. Active immunization against SRP® results in disabling bacterial cell wall receptor’s ability to acquire elemental iron, which is an essential bacterial nutrient for metabolism and survival in host animal tissues.
Other Proprietary Technologies
Epitopix also has proprietary technologies for sustained/delayed release vaccine formulation and for overriding maternal immunity in young animals. This technology is compatible with SRP®-based vaccines, and has been demonstrated to generate very desirable product attributes. Incorporation of these technologies into SRP®-based vaccines will provide exciting "next generation" vaccines and extended product lifecycles.